Deenova Wins First Private Contract in Spain for Hospital Centro de Andalucía de Lucena
Deenova announced today that its unrivalled market momentum unceasingly expands to Spain´s private hospital market, with its first award for won by Deenova in cooperation with Algalasa at Hospital Centro de Andalucía at Lucena, Cordoba, part of the new health enterprise Amaveca Salud.
Gaspar G. De Viedma, Vice Chairman of the Deenova Board of Directors stated:
“I am happy to see the first results of the Deenova´s cooperation with our partnership with Algalasa in such a short period of time, and together with our prior award at Bellvitge University Hospital in Barcelona to demonstrate once again Deenova´s unique scalability in hospitals ranging from 100 to 2.000 beds, with the installation of the ACCED and ASTUS mechatronic medication solutions in 2022.”
Jose Luis Temes, M.D., Algalasa’s President and former Sub-secretary of Health at Spain Ministry of Health, Director of National Health Service in Spain, and Managing Director of multiple Spanish hospitals, including Foundation Jimenez Diaz, Hospital La Paz, and Hospital Queen Sofia, added: “This milestone was possible thanks to the hospital owners understanding of the importance of closing the loop of the medication, from prescripti<on to patient administration, and the unique Deenova’s technology. Centro de Andalucía in Lucena will be a reference in patient safety, staff satisfaction, quality and efficiency of pharmacy processes.”
Hospital Centro de Andalucía de Lucena is located in the Andalucian city of Lucena in Cordoba. With 350 employees serving up to 200 beds, including surgery, a diagnostic area, analysis, a day hospital and physiotherapy, among other services. Its innovative new construction has been equipped with all kinds of details, such as domotic rooms, and patient entertainment systems (tablets, televisions, etc).
Deenova is the undisputed leading supplier of mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006013/en/
Contact information
Deenova:
Christophe Jaffuel, Elisa Mariotti
e.mariotti@deenova.com, +39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FoodChain ID Certifies Mulino Bianco’s Buongrano to Regenerative Agriculture (RGN) Standard13.10.2025 14:00:00 EEST | Press release
FoodChain ID today announced that Mulino Bianco’s Buongrano has been certified to the FoodChain ID Regenerative Agriculture (RGN) Certification, marking Italy’s first bakery brand to introduce a cookie certified with 100% regenerative soft wheat flour.1 The certification provides independent verification of regenerative outcomes and will be communicated on-pack via the FoodChain ID RGN mark, helping consumers identify products sourced from farms advancing soil health, biodiversity and climate resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013488950/en/ FoodChain ID today announced that Mulino Bianco’s Buongrano has been certified to the FoodChain ID Regenerative Agriculture (RGN) Certification, marking Italy’s first bakery brand to introduce a cookie certified with 100% regenerative soft wheat flour. FoodChain ID’s Regenerative Agriculture Certification is a globally applicable, outcome-based certification ali
World FZO Concludes Its 11 th World Congress in Hainan13.10.2025 13:14:00 EEST | Press release
The World Free Zones Organization concluded its 11th Annual World Congress in Hainan, hosted from October 10-12. The event attracted more than 1,200 participants from 70 countries, along with 16 high-level ministerial delegations and representatives of international economic and trade organisations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013845341/en/ HE Miguel Lecaro, Ambassador of the Republic of Panama to China, receiving the flag from H.E. Dr. Mohammed Al Zarooni (Photo: AETOSWire) The final day featured the Annual General Assembly meeting, during which a set of strategic resolutions aimed at enhancing the organisation’s operational framework and strengthening its global network of free zones was adopted. Elections were also held for the World FZO Board of Directors for a new term. The closing ceremony was attended by Liu Xiaoming, Governor of Hainan Province, alongside H.E. Dr. Mohammed Al Zarooni, Chairman o
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA13.10.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne’s request for participation in Project Orbis, an initiative that provides a framework for concurrent submission and review of oncology products among participating global health authorities. “Breakthrough Therapy Designation is reserved for medicines with the potential to transform outcomes for patients with serious diseases. This recognition affirms the strength of the emerging data for sonrotoclax and its potential to become a new standard of care for people with relapsed or refractory mantle cell lymphoma,” said Julie Lepin, Senior Vice President, Ch
Datassential Names Pascal Hartwig General Manager of EMEA, Releases First-Annual Top Chains in Europe Report13.10.2025 10:00:00 EEST | Press release
Datassential, the leading global food and beverage intelligence platform, announced the appointment of Pascal Hartwig as General Manager of EMEA. This expansion is part of Datassential's ongoing strategy to shape the future of food and beverage intelligence with a unified platform that delivers scale, speed, and precision for every customer type across the foodservice industry, including operators, manufacturers, distributors and suppliers. Hartwig’s leadership marks a pivotal step in positioning Datassential as the definitive source of truth in Europe, the Middle East, and Africa — building on its North American dominance to establish a stronger global footprint. Pascal was previously the Chief Product Officer at BeZero Carbon, and held senior leadership roles at S&P Global Market Intelligence. During his career, Pascal has established a strong track record in financial services, data solutions, product innovation and delivering value to customers. “Pascal's appointment reflects Datas
I-Pulse Welcomes Codelco as Strategic Investor13.10.2025 08:00:00 EEST | Press release
I-Pulse Co-Founder, Chairman and CEO Robert Friedland and Laurent Frescaline, Co-Founder and Chief Technology Officer, are pleased to welcome Codelco as the company’s latest strategic investor and key partner in the development and commercialization of its disruptive pulsed power technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251012216264/en/ I-Pulse Co-Founder Chairman and CEO Robert Friedland and Codelco Chairman Máximo Pacheco Codelco, the world’s largest copper miner, will provide capital and real-world experience to accelerate the commercialization of I-Pulse’s breakthrough innovations for drilling, continuous underground mining, tunnelling and rock crushing. Codelco joins world leading mining majors BHP, Ivanhoe Mines, Newmont, Rio Tinto, and Teck Resources in investing in I-Pulse and advancing the development of its family of technologies. Over nearly 20 years, I-Pulse has pioneered the application of hi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom